Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Failure to change the Antigenicity of Skin Grafts by Incubation with Allogeneic Ribonucleic Acid

Abstract

BALB/c skin grafts incubated with ribonucleic acid (RNA) from C3H mice were rejected when transplanted to syngeneic recipients1. Such grafts were rejected between 10 and 27 days after transplantation with a median survival time (MST) of 18 days. The MST of C3H skin on BALB/c recipients was 12.5 days.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Guttmann, R. D., Kraus, E. D., and Dolan, M. F., Nature, 203, 196 (1964).

    Article  ADS  CAS  Google Scholar 

  2. Billingham, R. E., and Medawar, P. B., J. Exp. Biol., 28, 385 (1951).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

ASKONAS, B., BRENT, L., GOWLAND, G. et al. Failure to change the Antigenicity of Skin Grafts by Incubation with Allogeneic Ribonucleic Acid. Nature 212, 1257–1258 (1966). https://doi.org/10.1038/2121257a0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/2121257a0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing